• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    MedReleaf Obtains Good Manufacturing Practices Certification

    Bryan Mc Govern
    Jun. 19, 2017 08:30AM PST
    Cannabis Investing News

    MedReleaf announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.

    MedReleaf (TSX:LEAF) announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
    As quoted in the press release:

    MedReleaf’s wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.
    Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.
    MedReleaf’s ICH-GMP certification will support the Company’s international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:

    • Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.
    • Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.
    • Accelerating MedReleaf’s partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical industryclinical trialscannabis investingaustraliacanadapharmaceutical and biotech companies
    The Conversation (0)

    Go Deeper

    AI Powered
    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies

    Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—